cyproheptadine has been researched along with Paraplegia in 4 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Paraplegia: Severe or complete loss of motor function in the lower extremities and lower portions of the trunk. This condition is most often associated with SPINAL CORD DISEASES, although BRAIN DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; and MUSCULAR DISEASES may also cause bilateral leg weakness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiserotonergic agent cyproheptadine was evaluated in six patients as a medication for the management of spasticity due either to spinal cord trauma or to multiple sclerosis." | 5.05 | Action of cyproheptadine in spastic paraparetic patients. ( Barbeau, H; Bédard, PJ; Richards, CL, 1982) |
| "To evaluate spasticity in a dynamic, voluntary movement such as locomotion, a task-specific approach is essential." | 1.28 | A dynamic EMG profile index to quantify muscular activation disorder in spastic paretic gait. ( Barbeau, H; Fung, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbeau, H | 3 |
| Richards, CL | 1 |
| Bédard, PJ | 1 |
| Siegal, T | 2 |
| Wainberg, M | 1 |
| Gauthier, S | 1 |
| Fung, J | 1 |
2 trials available for cyproheptadine and Paraplegia
| Article | Year |
|---|---|
Action of cyproheptadine in spastic paraparetic patients.
Topics: Adult; Cyproheptadine; Electromyography; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Musc | 1982 |
The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries.
Topics: Adult; Cyproheptadine; Double-Blind Method; Drug Administration Schedule; Electromyography; Exercise | 1990 |
2 other studies available for cyproheptadine and Paraplegia
| Article | Year |
|---|---|
Participation of serotonergic mechanisms in the pathophysiology of experimental neoplastic spinal cord compression.
Topics: Animals; Anti-Inflammatory Agents; Body Water; Capillary Permeability; Cyproheptadine; Dinoprostone; | 1991 |
A dynamic EMG profile index to quantify muscular activation disorder in spastic paretic gait.
Topics: Adult; Cyproheptadine; Electromyography; Humans; Leg; Locomotion; Male; Middle Aged; Muscle Spastici | 1989 |